Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Swiss pharma giant Roche today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20–24 September 2021. 24 September 2021
Otsuka Pharmaceutical company Astex Pharmaceuticals has provided new Phase III data from the ASCERTAIN trial of Inqovi (decitabine/cedazuridine). 24 September 2021
R-Pharm, one of Russia’s leading drugmakers, has started the production of a vaccine against COVID-19 under a license from Oxford University and UK pharma major AstraZeneca, according to recent statements made by some Russian state officials and local media reports. 24 September 2021
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and how they impact its future. 24 September 2021
The World Health Organization's Director General Tedros Adhanom Ghebreyesus has thanked India's Minister Mansukh Mandaviya for announcing that India will resume crucial COVID-19 vaccine shipments to COVAX in October. 23 September 2021
Research undertaken at the University of Bristol, UK, paves the way for a novel artificial intelligence (AI)-driven platform for growing and treating virtual tumors. 22 September 2021
Research from industry analyst GlobalData finds an increasing rate of dealmaking in India in recent quarters, propelled by the coronavirus pandemic. 21 September 2021
Uwe Trinks, global practice lead for pharmacovigilance technologies, IQVIA, provides an Expert View on how the pharmaceutical industry can make a success of new working practices. 21 September 2021
In a world reeling from the coronavirus pandemic, the pharmaceutical industry has been leading the global response, not only for its enormous contribution to the management of COVID-19, but also for its tireless commitment to continue developing therapies for different diseases that afflict populations. 21 September 2021
Anglo-Swedish pharma major AstraZeneca today revealed plans to establish a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland, to ensure the company’s global supply network is fit for future growth. 21 September 2021
At the annual congress of the European Society of Medical Oncology (ESMO), Swiss drugmaker Novartis has announced important new data for its CDK4/6 inhibitor Kisqali (ribociclib). 20 September 2021
At the annual congress of the European Society of Medical Oncology (ESMO 2021), Japan’s Astellas Pharma and partner Pfizer are offering new data for Xtandi (enzalutamide). 17 September 2021
Spanish plasma specialist Grifols today proposed a 1.6 billion-euro ($1.9 billion) takeover of its German rival Biotest, in a move to consolidate the plasma-based drug industry. , 17 September 2021
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit of AbbVie and Roche’s Venclexta/Venclexto (venetoclax) in combination with a hypomethylating agent (HMA) offers an added benefit over the appropriate comparator therapy for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. 17 September 2021